The recent FDA approval of an oral version of semaglutide specifically for weight loss (distinct from Rybelsus , which is used for diabetes) represents a major leap in patient convenience
We may see you more often for these additional services, depending on the package you choose
If someone is actively restricting intake beyond what the medication is already doing, they may experience symptoms like irritability or mood swings
The data suggest that GLP-1-induced weight loss includes both fat mass and lean mass reduction, with approximately 25-40% of total weight loss coming from lean tissue
The key difference is that Retatrutide is designed as a triple agonist, with activity at GLP-1, GIP, and glucagon receptors
Rather than targeting obesity through a single mechanism, this 3-way agonist addresses the complex hormonal and metabolic networks that regulate body weight, treating obesity as the multifaceted metabolic disease it truly is